Malocide (Pyrimethamine)

Pyrimethamine blocks the enzyme dihydrofolate reductase in malaria‑causing Plasmodium and Toxoplasma parasites. By preventing folate conversion, it stops DNA synthesis and cell division within the organisms, leading to their death while minimally affecting human cells that use a different enzyme isoform.

The dosage of Malocide is determined by the prescribing clinician based on the specific indication, patient weight, age, renal and hepatic function, and any concomitant therapies. Healthcare professionals tailor the regimen to achieve optimal therapeutic outcomes while minimizing risk.

Safety data for pyrimethamine in pregnancy and lactation are limited, and the pregnancy category is unknown. It should only be used when clearly needed and after a risk‑benefit assessment by a qualified healthcare provider. Breastfeeding mothers should consult their physician before use.

To request Malocide, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Malocide (pyrimethamine) is often combined with sulfadoxine for synergistic antimalarial effect, differing from agents like chloroquine or artemisinin derivatives that target other parasite pathways. Its mechanism focuses on folate metabolism, which can be advantageous in resistant strains but may require folic acid supplementation to mitigate hematologic toxicity.

Malocide should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Maintaining these conditions helps preserve tablet integrity and potency throughout its shelf life.

Malocide is taken orally, usually as a tablet, with or without food as directed by the prescriber. The exact administration schedule, including any loading or maintenance doses, is defined by the treating clinician based on the infection being addressed.

The most serious adverse events linked to pyrimethamine include bone‑marrow suppression leading to anemia, leukopenia or thrombocytopenia, severe skin reactions such as Stevens‑Johnson syndrome, and hepatic dysfunction. Prompt monitoring of blood counts and liver enzymes is essential during therapy.

Patients with known hypersensitivity to pyrimethamine or any component of the formulation should avoid Malocide. Individuals with severe bone‑marrow disorders, uncontrolled hepatic disease, or those taking contraindicated medications such as certain sulfonamides should not use this product without specialist guidance.